Latest Duchenne muscular dystrophy Stories
MDA research grantee Charles Gersbach announces potentially game-changing advance in gene modification for boys and young men with DMD. Chicago, IL (PRWEB) February
Leading Duchenne organizations partner to enable long-term trials of novel anti-inflammatory drug; chronic toxicology studies will pave regulatory path to Phase 2a studies later this year
PPMD's Annual Advocacy Conference Focused on Implementing MD-CARE Act Amendments & Strengthening Patient Voice at FDA WASHINGTON, Feb.
Product holds potential for replacing glucocorticoids in Duchenne muscular dystrophy and other chronic inflammatory states SILVER SPRING, Md. and CHICAGO, Feb.
HACKENSACK, N.J., Feb.
Leading Duchenne Organization Continues to Certify Top Clinics Nationally HACKENSACK, N.J., Feb.
Researchers at Nationwide Children's Hospital have developed a way to measure upper extremity movement in patients with muscular dystrophy using interactive video game technology. Their hope is to expand inclusion criteria for clinical trials to incorporate patients using wheelchairs.
HACKENSACK, N.J., Jan.
Researchers may soon test new drugs and study diseases in functioning human muscles thanks to biomedical engineers at Duke University, who have, for the first time, grown contracting human muscles in a laboratory.
Former Program Director at NIH/NINDS Offers Years of Rare Disease Research Experience HACKENSACK, N.J., Jan.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.